$7.2M in expenses

Ovarian cancer research alliance was founded in 1994 (as the ovarian cancer research fund, INC.) and is a full-spectrum organization funding medical research, advocating on behalf of patients and providing support and resources to patients and their families.ovarian cancer is the deadliest of all gynecologic cancers and ranks fifth as the cause of cancer death in women. In 2024, there were 19,680 new cases of ovarian cancer and 12,740 deaths from the disease in the united states. The accomplishments of ocra's programs reflect our commitment to the ovarian and gynecologic cancer communities. Since 1998, ocra has awarded 435 grants for ovarian and related cancer research to physicians and scientists at 99 leading medical centers, which is an investment totaling over $129 million. Thanks to the generosity of our donors, our investigators are working on many fronts to defeat ovarian cancer. By developing innovative strategies for early detection and exploring the genetics that increase risk for ovarian cancer, we hope to save women's lives by finding the cancer early or stopping it before it even starts. Researchers are gaining insights into the many types of ovarian and related cancers to determine the origins, which may lead to more effective testing and effective immunotherapy treatment options. Furthermore, they are identifying new and better treatments to improve overall survival, prevent drug resistance, minimize side effects, preventing recurrence and metastasis, and enhance patients' quality of life. Ocra continued the health equity research grants begun in 2023. These grants focus on improving health equity in the gynecologic cancer space.accomplishments achieved as a result of ocra grants include:identified a molecule that could be key to improving immune response against ovarian cancer; highlighted the need for individual assessment of complex variants to correctly identify individuals at risk; sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant cancer cells) may offer a solution; identified a previously unknown chemoresistant pathway in HGSC which led to working on a new therapy to overcome this; found that mesothelial cells are important to the initial stages of ovarian cancer growth in the abdominal cavity; shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that allows malignancies in the fallopian tube to migrate to the ovaries and continue to grow; uncovered several mechanisms of immune escape to help explain some ovarian cancers' resistance to immunotherapy; shown that rucaparib extends progression free survival in ovarian cancer; discovered that 18% of ovarian cancer cases involve inherited mutations; pinpointed two genes that trigger ovarian cancer; identified a new therapeutic strategy for clear cell ovarian cancer; shown how a parp/immune therapy combo shows promise; demonstrated how gene therapy may help patients with recurrent disease; shed light on how ovarian cancer grows; discovered that analyzing data from pap smears could help detect endometrial and ovarian cancer; established there is no link between obesity and risk for the most common type of ovarian cancer; shown that fgfr4 is a prognostic marker and therapeutic target for ovarian cancer; defined similarities between some endometrial, breast and ovarian cancers; explained how an experimental drug may be helpful in fighting platinum-resistant ovarian cancer; identified areas of the human genome that are linked to increased risk for ovarian cancer; identified biomarkers that can be used to monitor the development of platinum resistance therapies; studied macrophages to improve treatment; identified novel biomarkers of hgsoc and specific drug targets; targeted mdm2 degradation as a novel treatment for ovarian cancer; used machine learning to bridge the gap between disparate data sets specifically in patients with hgsoc; dosed the first patients in the clinical trial "immunotherapy platform study in platinum resistant high grade serous ovarian cancer (iproc)" (nct04918186); found key proteins in hgsoc cancer cells which resulted in combined treatment options which resulted in smaller tumors and longer survival; and showed how surgical removal of fallopian tubes may reduce ovarian cancer risk.in 2024 alone, ocra researchers: developed a possible framework for the development of novel strategies to improve treatment outcomes; showed how rnf168 produces and reads chromatin ubiquitylation; uncovered several mechanisms of immune escape to help explain some ovarian cancers' resistance to immunotherapy; found a decrease in ovarian carcinoma incidence after salpingectomy for treating ectopic pregnancy; showed parp1 is involved in repair of telomeres, and that impairing this process can lead to telomere shortening and genomic instability that can cause cancer; developed a proof of concept study to show how three dimensional modeling can show how cancer cells and car-t interact which will hopefully lead to better treatments in patients with hgsoc solid tumors; discovered that aggressive ovarian cancers often show sudden large-scale DNA damage, pointing to distinct origins and detection strategies; characterized expression of nearly 500 proteins from thousands of cancer samples, enabling insights into tumor heterogeneity, cancer dependencies, biomarkers, and therapeutic targets; discovered that a protein called egfl6 helps ovarian tumors block the immune system's attack, but blocking egfl6 restored the effectiveness of immunotherapy in mice, suggesting a promising new treatment target; and identified that loss of a gene called smarca4 makes ovarian cancer cells more visible to the immune system, boosting immune attack and suggesting a new strategy to improve immunotherapy.every dollar donated brings us closer to a cure for this devastating disease. For more information or to join us in our fight, please visit ocra's website at WWW.ocrahope.org.

$1.7M in expenses

Beyond our conference, ocra has additional patient education and support programs and engages in advocacy on behalf of women with gynecologic cancers. Our website is a comprehensive source of educational information, and throughout the course of the year we hold a series of free, educational webinars on a range of topics related to the latest research, treatment, and survivorship.ocra offers free genetic testing to qualified high risk individuals and facilitates access to certified genetic counselors. Since the launch of the program, ocra has helped over 3,000 people learn about their genetic risk for gynecologic cancer. Ocra's patient-support line is staffed by our social work team during business hours monday through friday and is available to anyone seeking information, support, patient navigation, or resource referrals (medical advice is not provided). Our woman to woman program is a peer-to-peer support program for women with gynecologic cancer. Ocra offers both a national woman to woman program and provides financial support to help hospitals and other organizations start local woman to woman programs, which are now at more than 19 sites across the country. Our staying connected support series, which launched in 2020, now offers four weekly workshops and three monthly workshops which provide all impacted by ovarian or related gynecologic cancers a way to learn, share, and connect. Our arts program-express yourself and book club- offers a combination of therapeutic arts, poetry, reading and creative expression, and community building activities with 1865 registered in 2024. Ocra partners with inspire.com to offer an online support community that has over 85,000 members world-wide.ocra is committed to encouraging the next generation of healthcare professionals to focus on the critical needs of those diagnosed with gynecologic cancer, whether at bench or bedside.through ocra's oncology social work field placement, we accept top master of social work candidates to train with our licensed clinical social workers to address the specific needs of our community.ocra's survivors teaching students (STS) program trains ovarian cancer survivors and caregivers to conduct presentations in medical education programs to educate future healthcare providers about ovarian cancer. Survivors share their stories of diagnosis, treatment and beyond, along with facts about the disease. In 2024, more than 980 survivor volunteers delivered 439 presentations in the us, UK, and australia reaching over 10,000 medical, nursing, and physician's assistant students. These presentations ensure the next generation of health care providers understand basic facts about the disease, are aware of risk factors, and can identify the signs and symptoms of ovarian cancer, helping ensure a timely diagnosis.ovarian cancer research alliance is a powerful voice on capitol hill, in statehouses around the country and with federal agencies for everyone touched by gynecologic cancer. Each year ocra plays a critical role in helping to secure more than $200 million in federal funding for ovarian cancer research and education. In addition, our growing advocate leader program trains members of the gynecologic cancer community to raise awareness through news articles and outreach, develop relationships with their elected officials, and fight for increased funding for gynecologic cancer research throughout the country.

$983K in expenses

Each year, ocra brings together ovarian cancer patients, survivors and caregivers at the international gynecologic cancer conference, a three day-long event filled with informational sessions featuring expert speakers, fun and community. In 2024, more than 600 people from all 50 states and 14 countries came together virtually for this event. The spirit of unity and hope is always strong and attendees can learn more about their diagnosis, treatment, and survivorship. Sessions feature top ovarian and gynecologic cancer experts who generously give of their time, presenting the latest in treatments, research, managing recurrence, genetics, nutrition, caretaker and supporter care, support for young women, advocacy, and so much more.